ClassID:

20992

A61K38/2271 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Neuropeptide Y

Recent Application in this class:
#1
20260097101
2026-04-09

Compositions for Use in the Treatment of Diabetes or Obesity

#2
20240197912
2024-06-20

A PHARMACEUTICALLY ACCEPTABLE AQUEOUS GEL COMPOSITION FOR MRNA DELIVERY

#3
20240091318
2024-03-21

COMBINATION THERAPY COMPRISING LONG ACTING GLP-1/GLUCAGON AND NPY2 RECEPTOR AGONISTS

#4
20220249605
2022-08-11

Treatment of Mood and Anxiety Disorders

#5
20220241377
2022-08-04

RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES

#6
20220143147
2022-05-12

INTRANASAL NEUROPEPTIDES FOR USE IN STRESS-RELATED IMPAIRMENTS

#7
20210163567
2021-06-03

Method of Delivering a Centrally-Acting Peptide Derivative, and Method of Treating a Neuropsychiatric Disorder

#8
20210154272
2021-05-27

NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE

#9
20200087372
2020-03-19

Acylated glucagon analogue

#10
20200046963
2020-02-13

System for the transdermal delivery of active ingredient

#11
20200023083
2020-01-23

METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES

#12
20190240293
2019-08-08

NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE

#13
20190083455
2019-03-21

METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS

#14
20190002517
2019-01-03

NEUROPEPTIDE Y-DERIVED PEPTIDES

#15
20180271947
2018-09-27

Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor

#16
20180094038
2018-04-05

Acylated glucagon analogue

#17
20170281672
2017-10-05

Systems and methods for delivery of peptides

#18
20170267723
2017-09-21

Peptides for treating bone diseases and use thereof

#19
20170224781
2017-08-10

Method using an Y1 receptor activator for treating an anticancer agent-induced nephrotoxic injury

#20
20170189491
2017-07-06

Composition containing neuropeptide Y for inhibiting side effects of anticancer agents

#21
20170095543
2017-04-06

METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS

#22
20170095536
2017-04-06

Methods and compositions for managing reproduction

#23
20170081367
2017-03-23

Peptides for preventing or treating bone diseases and use thereof

#24
20170079908
2017-03-23

Compositions and methods for affecting mood states

#25
20170020951
2017-01-26

Neuropeptide analogs, compositions, and methods for treating pain

#26
20160367639
2016-12-22

MODIFICATION OF FEEDING BEHAVIOR

#27
20160303361
2016-10-20

System for the transdermal delivery of active ingredient

#28
20160279204
2016-09-29

PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT BY NASAL ADMINISTRATION OF PATIENTS SUFFERING FROM ANXIETY AND SLEEP DISORDERS

#29
20160243198
2016-08-25

Pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as active ingredient

#30
20160158279
2016-06-09

Systems and methods for delivery of peptides

#31
20160136087
2016-05-19

Compositions and methods for affecting mood states

#32
20160114053
2016-04-28

Methods and compositions for delivering active agents with enhanced pharmacological properties

#33
20160060320
2016-03-03

Neuropeptide Y-derived peptides

#34
20160045609
2016-02-18

CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE

#35
20150322128
2015-11-12

Dual GLP-1/glucagon receptor agonists derived from exendin-4

#36
20150174063
2015-06-25

Oral administration of tocilizumab treatment of autoimmune disease

#37
20140322341
2014-10-30

NOVEL HEMOSTATIC PATCH AND USES THEREOF

#38
20140271808
2014-09-18

Systems and methods for delivery of peptides

#39
20140271805
2014-09-18

Compositions and methods for affecting mood states

#40
20140135261
2014-05-15

PEPTIDE YY AND PEPTIDE YY AGONISTS FOR TREATMENT OF METABOLIC DISORDERS

#41
20130338214
2013-12-19

Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell

#42
20130259901
2013-10-03

Neuropeptide Y treatment of autoimmune disease

#43
20130023466
2013-01-24

Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders

#44
20120263790
2012-10-18

Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions

#45
20120245104
2012-09-27

NOVEL RETRO-INVERSO LEPTIN PEPTIDE ANTAGONISTS

#46
20120202288
2012-08-09

COMPOSITIONS COMPRISING CYCLIC AMP ENHANCERS AND/OR EP LIGANDS, AND METHODS OF PREPARING AND USING THE SAME

#47
20120040893
2012-02-16

MODIFICATION OF FEEDING BEHAVIOUR

#48
20120040886
2012-02-16

Analogues of Neuropeptide Y Having Proline Substitution At Position 34

#49
20110251126
2011-10-13

INTESTINAL TREATMENT

#50
20110230399
2011-09-22

Methods for Treating Obesity Related Disease

#51
20110021422
2011-01-27

Method and compositions for prevention and treatment of diabetic and aged skin

#52
20110021420
2011-01-27

MODIFICATION OF FEEDING BEHAVIOUR

#53
20100292149
2010-11-18

Modulation of the Neuroendocrine System as a Therapy for Motor Neuron Disease

#54
20100209507
2010-08-19

Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions

#55
20100179093
2010-07-15

Neoropeptide-2-Receptor (Y-2R) Agonists

#56
20090317376
2009-12-24

Compositions And Methods For Lipo Modeling

#57
20090213731
2009-08-27

USE OF NEUROPEPTIDE Y (NPY) AND AGONISTS AND ANTAGONISTS THEREOF FOR TISSUE REGENERATION

#58
20090186811
2009-07-23

Y2 Selective Receptor Agonists for Therapeutic Interventions

#59
20090062203
2009-03-05

Dipeptidyl peptidase IV inhibitors for the treatment of schizophrenia and depression

#60
20080242595
2008-10-02

Conjugate of insulin and vitamin B12 for oral delivery

#61
20080167217
2008-07-10

Aryl ketone compounds and compositions for delivering active agents

#62
20080064636
2008-03-13

Modification of feeding behaviour

#63
20080004218
2008-01-03

METHODS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES FOR TREATING AND PREVENTING OBESITY

#64
20070197437
2007-08-23

COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES

#65
20070142291
2007-06-21

Methods for treating irritable bowel syndrome

#66
20070129299
2007-06-07

COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE

#67
20060252701
2006-11-09

Dipeptidyl peptidase IV inhibitors for the treatment of anxiety

#68
20060246085
2006-11-02

Methods for manipulating satiety

#69
20060204471
2006-09-14

Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging

#70
20060193871
2006-08-31

Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia

#71
20060189522
2006-08-24

Modification of feeding behaviour

#72
20060178306
2006-08-10

Modulation of the neuroendoctrine system as a therapy for motor neuron disease

#73
20060147496
2006-07-06

Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions

#74
20060030942
2006-02-09

Use of neuropeptides for ligament healing

#75
20060014678
2006-01-19

Modification of feeding behavior using PYY and GLP-1

#76
20050014742
2005-01-20

Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism

#77
20050014693
2005-01-20

Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia

#78
20050002927
2005-01-06

Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity